Literature DB >> 12744850

The effectiveness and safety of hepatitis A vaccine: a systematic review.

Vittorio Demicheli1, Donatella Tiberti.   

Abstract

We report on the conduct of a systematic review to assess the efficacy and the safety of hepatitis A vaccines in adults and children. We identified, retrieved, and assessed all trials evaluating the effects of hepatitis A vaccines on prevention of cases of hepatitis A, death from hepatitis A, and assessing nature and frequency of adverse events. We included eight randomised trials, four containing efficacy outcomes, three containing only safety outcomes and a single study containing efficacy and adverse events outcomes. Combined inactivated vaccine effectiveness was 86% (95% CI: 63-95%). Combined attenuated vaccine effectiveness was 95% (95% CI: 81-99%). Inactivated vaccine effectiveness in the prevention of HAV secondary cases, compared to non-intervention was 82% (95% CI: 23-96%). Safety profile of vaccines was similar to that of their comparators. Despite poor design and reporting of trials, we found convincing evidence of the effectiveness and safety of inactivated HAV vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744850     DOI: 10.1016/s0264-410x(03)00135-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor.

Authors:  Ming-Bo Sun; Yan-Jun Jiang; Wei-Dong Li; Ping-Zhong Li; Guo-Liang Li; Shu-De Jiang; Guo-Yang Liao
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

2.  Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.

Authors:  Ignasi Parrón; Caritat Planas; Pere Godoy; Sandra Manzanares-Laya; Ana Martínez; Maria Rosa Sala; Sofia Minguell; Nuria Torner; Mireia Jané; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

Review 3.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

4.  An outbreak of hepatitis A among children and adults in Denmark, August 2002 to February 2003.

Authors:  A Gervelmeyer; M Søborg Nielsen; L Chemnitz Frey; H Sckerl; E Damberg; K Mølbak
Journal:  Epidemiol Infect       Date:  2005-09-30       Impact factor: 2.451

5.  The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis.

Authors:  Eduardo Lopez; Roberto Debbag; Laurent Coudeville; Florence Baron-Papillon; Judith Armoni
Journal:  J Gastroenterol       Date:  2007-03-12       Impact factor: 7.527

Review 6.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

7.  Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United States.

Authors:  Emmanuelle A Dankwa; Christl A Donnelly; Andrew F Brouwer; Rui Zhao; Martha P Montgomery; Mark K Weng; Natasha K Martin
Journal:  Vaccine       Date:  2021-10-20       Impact factor: 4.169

8.  [Prevention and therapy of viral hepatitis].

Authors:  H M Diepolder
Journal:  Internist (Berl)       Date:  2004-02       Impact factor: 0.743

9.  The Impact of Vaccination Efforts on the Spatiotemporal Patterns of the Hepatitis A Outbreak in Michigan, 2016-2018.

Authors:  Andrew F Brouwer; Jonathan L Zelner; Marisa C Eisenberg; Lynsey Kimmins; Macey Ladisky; Jim Collins; Joseph N S Eisenberg
Journal:  Epidemiology       Date:  2020-09       Impact factor: 4.860

10.  Evaluating Partial Series Childhood Vaccination Services in a Mobile Clinic Setting.

Authors:  Weiwei Chen; Sanghamitra M Misra; Fangjun Zhou; Leila C Sahni; Julie A Boom; Mark Messonnier
Journal:  Clin Pediatr (Phila)       Date:  2020-02-28       Impact factor: 1.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.